Author

A. R. Cortazar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Carracedo· 3 shared A. M. Aransay· 3 shared R. Barrio· 2 shared U. Mayor· 2 shared A. C. O. Vertegaal· 1 shared A. Loizaga· 1 shared A. Macchia· 1 shared A. S. Schober· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

A. Carracedo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Identification of proximal SUMO-dependent interactors using SUMO-ID

O. Barroso-Gomila, F. Trulsson, V. Muratore, I. Canosa, L. Merino-Cacho, A. R. Cortazar, C. Perez, M. Azkargorta, I. Iloro, A. Carracedo, A. M. Aransay, F. Elortza, U. Mayor, A. C. O. Vertegaal, R. Barrio, J. D. Sutherland

This study introduces SUMO-ID, a method to identify SUMO-dependent protein interactors using TurboID and protein-fragment complementation, revealing novel interactions related to transcription, DNA damage, and stress response.

bioRxiv · Dec 28, 2020Biochemistry

USP29 is a novel non-canonical Hypoxia Inducible Factor-α activator

A. S. Schober, I. Martin-Barros, T. Martin-Mateos, E. Perez-Andres, O. Carlevaris, S. Pozo, A. R. Cortazar, A. M. Aransay, A. Carracedo, U. Mayor, V. See, E. Berra

This study identifies USP29 as a non-canonical activator of HIF-α that stabilizes HIF-1 and HIF-2 independently of oxygen, PHD, and pVHL, and correlates with disease progression in prostate cancer.

bioRxiv · Feb 20, 2020 · PreprintCell Biology

Integrative analysis of transcriptomic and clinical data uncovers the tumor suppressive activity of MITF in prostate cancer.

L. Valcarcel, A. Macchia, N. Martin, A. R. Cortazar, A. Schaub, M. Pujana, S. Fernandez, I. Lacasa, A. Santos, A. Loizaga, M. Unda, I. Hermanova, I. Astobiza, M. Graupera, J. Starkova, , V. Torrano

The paper identifies MITF as a tumor suppressor in prostate cancer and reveals CRYAB as a direct target mediating its suppressive activity through integrative transcriptomic and clinical analysis.

bioRxiv · Aug 14, 2018Cancer Biology